Searching for Early Blood Lipid Markers of Diabetic Kidney Disease
Compares blood lipids in adults with type 2 diabetes to find early kidney damage signs.
Plain-language title generated from the registry record
Registry title: Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 to 80 who have signed consent and can be followed for more than 5 years. It studies blood fats (lipids) as early markers of diabetic kidney disease.
- Age
- 20 to 80 years (the registry header lists 18 to 80 years).
- Sex
- Women and men can join.
- Disease stage
- Not stated in the inclusion criteria. The study looks at early diabetic kidney disease, type 2 diabetes and healthy adults.
Main reasons for not taking part
- Kidney disease from other causes
- Acute infections of any kind
- Expected life expectancy of less than 5 years
- Drug users or drug abusers
- Active hepatitis, AIDS, syphilis or tuberculosis
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04931537, who can take part
Where in China
- the Second Affiliated Hospital Zhejiang University Schoolof MedicineHangzhou, ChinaContact: Chao Zheng, MD. PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT04931537
- Record updated
- 20 July 2021
- Original description
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.Read full original descriptionShow less
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD). Albuminuria and estimated glomerular filtration rate (eGFR) are currently recognized clinical indicators for early diagnosis of DN, however, the sensitivity and specificity are unsatisfactory. The early identification and treatment of DKD are conducive to lowering the risk of kidney damage by as much as 50%. Therefore, it is particularly critical to find new biomarkers to reflect the potential DKD lesions in the clinical silent period earlier and more accurately. Therefore, this study intends to analyze the differentially expressed lipids in early DKD, T2DM and healthy adults by mass spectrometry, and verify the related results by larger samples, so as to screen out early markers of DKD and achieve the ultimate goal of clinical application.
Inclusion: Subjects who have signed informed consent; Subjects were 20-80 years old and of either gender; Subjects showed good compliance, and the follow-up data was available for >5 years.
Exclusion: Drug users or drug abusers; Renal diseases caused by other causes, including primary and secondary; All kinds of acute infections; The expected life expectancy (life expectancy or related diseases) was less than 5 years according to the researcher's judgment; Sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis are in an active period; Meet the 1999 World Health Organization (WHO) diagnostic criteria for T1DM、T2DM; Any situation judged by the researcher that affects enrollment.